NCT00756249View on ClinicalTrials.gov

Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

December 31, 2008

Conditions
Acute Ischemic Stroke
Interventions
DRUG

Lu AA24493 (CEPO)

0.005 - 50.0 mcg/kg body weight, IV, within 12-48 hrs from symptom onset

DRUG

Placebo

Vials with solution for IV infusion

Trial Locations (5)

75018

FR002, Paris

119074

SG003, Singapore

00029 HUS

FI004, Helsinki

4818 CK

NL005, Breda

G11 6NT

GB001, Glasgow

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT00756249 - Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke | Biotech Hunter | Biotech Hunter